Clinical Manifestations and Myositis-Specific Autoantibodies Associated with Physical Dysfunction after Treatment in Polymyositis and Dermatomyositis: An Observational Study of Physical Dysfunction with Myositis in Japan

Table 3

A comparison of autoantibody profiles between PM/DM patients with and those without physical dysfunction.

	Physical normal function ()	Physical dysfunction ()	P value
Myositis-specific autoantibodies, number (%)
Anti-ARS	16 (34)	6 (29)	0.62
Anti-MDA5	7 (15)	0 (0)	0.09
Anti-Mi-2	1 (2)	1 (5)	0.53
Anti-NXP-2	2 (4)	0 (0)	1.00
Anti-SRP	3 (7)	6 (29)	0.02
Anti-TIF1-	3 (7)	1 (5)	0.89
Myositis-associated autoantibodies, number (%)	7 (21)	6 (14)	0.38
Anti-Ku	3 (7)	0 (0)	0.55
Anti-U1-snRNP	6 (13)	4 (19)	0.71
Anti-SS-A	21 (46)	9 (43)	1.00

Physical dysfunction was defined as a J-HAQ-DI score greater than 0.5.
Statistical analyses were performed using the Mann-Whitney test.
P values <0.05.
PM: polymyositis; DM: dermatomyositis; ARS: aminoacyl-tRNA synthetase; MDA5: melanoma differentiation-associated gene 5; NXP-2: nuclear matrix protein-2; SRP: signal recognition particle; TIF1-: transcriptional intermediary factor 1-.